Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94

Benzinga · 2d ago
Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price target from $97 to $94.